宜明昂科-B(01541.HK)拟配售2420万股总筹3.51亿港元加码肿瘤药物研发

中金财经

Oct 09, 2025

　　格隆汇10月9日丨宜明昂科-B(01541.HK)发布公告，2025年10月9日(交易时段前)，公司与配售代理(即瑞银集团)订立配售协议，据此，配售代理已同意担任公司的独家配售代理，尽力促使认购人按配售协议所载条款及在受该协议所载条件的规限下以每股配售股份14.50港元的配售价认购合共2420万股新H股。　　每股配售股份14.50港元的配售价较H股于最后交易日在联交所所报收市价每股16.66港元折让约12.97%。配售股份分别占公司于本公告日期的已发行股本及已发行H股总数约5.94%及约6.11%。配售股份将根据一般授权配发及发行。　　公司自配售事项收取的所得款项总额及所得款项净额估计分别为约3.509亿港元及约3.451亿港元。公司拟将配售事项所得款项净额应用于以下用途：约40%将用于为在中国进行IMM2510及IMM27M的单一疗法及联合疗法的研发提供资金以治疗实体瘤；约20%将用于为IMM01(替达派西普)的研发提供资金；约10%将用于为IMM0306的研发提供资金；及约30%将用于补充公司营运资金，并作一般企业用途。　　　　【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱：news_center@staff.hexun.com 　　

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2574904296"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2574904296\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2574904296?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-10-09 08:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2574904296","market":"sh","top_or_hot":-1,"title":"宜明昂科-B(01541.HK)拟配售2420万股总筹3.51亿港元 加码肿瘤药物研发","media":"中金财经","content":"<html><body><p>　　格隆汇10月9日丨<a href=\"https://laohu8.com/S/01541\">宜明昂科-B</a>(01541.HK)发布公告，2025年10月9日(交易时段前)，公司与配售代理(即瑞银集团)订立配售协议，据此，配售代理已同意担任公司的独家配售代理，尽力促使认购人按配售协议所载条款及在受该协议所载条件的规限下以每股配售股份14.50港元的配售价认购合共2420万股新H股。\r\n\r\n　　每股配售股份14.50港元的配售价较H股于最后交易日在联交所所报收市价每股16.66港元折让约12.97%。配售股份分别占公司于本公告日期的已发行股本及已发行H股总数约5.94%及约6.11%。配售股份将根据一般授权配发及发行。\r\n\r\n　　公司自配售事项收取的所得款项总额及所得款项净额估计分别为约3.509亿港元及约3.451亿港元。公司拟将配售事项所得款项净额应用于以下用途：约40%将用于为在中国进行IMM2510及IMM27M的单一疗法及联合疗法的研发提供资金以治疗实体瘤；约20%将用于为IMM01(替达派西普)的研发提供资金；约10%将用于为IMM0306的研发提供资金；及约30%将用于补充公司营运资金，并作一般企业用途。\r\n\r\n　　\r\n\r\n　　【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱：news_center@staff.hexun.com\r\n\r\n　　 </p></body></html>","source":"zhongjincaijing_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>宜明昂科-B(01541.HK)拟配售2420万股总筹3.51亿港元 加码肿瘤药物研发</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n宜明昂科-B(01541.HK)拟配售2420万股总筹3.51亿港元 加码肿瘤药物研发\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-09 08:47 北京时间&nbsp;&nbsp;&nbsp;<a href=http://sc.stock.cnfol.com/gushizhibo/20251009/31691363.shtml><strong>中金财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>格隆汇10月9日丨宜明昂科-B(01541.HK)发布公告，2025年10月9日(交易时段前)，公司与配售代理(即瑞银集团)订立配售协议，据此，配售代理已同意担任公司的独家配售代理，尽力促使认购人按配售协议所载条款及在受该协议所载条件的规限下以每股配售股份14.50港元的配售价认购合共2420万股新H股。\r\n\r\n　　每股配售股份14.50港元的配售价较H股于最后交易日在联交所所报收市价每股...</p>\n\n<a href=\"http://sc.stock.cnfol.com/gushizhibo/20251009/31691363.shtml\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20251009/31691363.shtml","article_id":"2574904296","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2574904296","pubTimestamp":1759970821,"columns":[],"sourceInfo":{"source_id":"zhongjincaijing_highlight","name":"中金在线"},"weMediaInfo":null,"summary":"格隆汇10月9日丨宜明昂科-B发布公告，2025年10月9日，公司与配售代理订立配售协议，据此，配售代理已同意担任公司的独家配售代理，尽力促使认购人按配售协议所载条款及在受该协议所载条件的规限下以每股配售股份14.50港元的配售价认购合共2420万股新H股。配售股份分别占公司于本公告日期的已发行股本及已发行H股总数约5.94%及约6.11%。配售股份将根据一般授权配发及发行。","collect":0,"end_time":0,"defaultTopTitle":"cnfol.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1161":"生物科技","01541":"宜明昂科-B"},"translate_title":"Yiming Angke-B (01541. HK) plans to place 24.2 million shares to raise a total of HK $351 million to increase the research and development of oncology drugs","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01541":1.5},"content_text":"格隆汇10月9日丨宜明昂科-B(01541.HK)发布公告，2025年10月9日(交易时段前)，公司与配售代理(即瑞银集团)订立配售协议，据此，配售代理已同意担任公司的独家配售代理，尽力促使认购人按配售协议所载条款及在受该协议所载条件的规限下以每股配售股份14.50港元的配售价认购合共2420万股新H股。\r\n\r\n　　每股配售股份14.50港元的配售价较H股于最后交易日在联交所所报收市价每股16.66港元折让约12.97%。配售股份分别占公司于本公告日期的已发行股本及已发行H股总数约5.94%及约6.11%。配售股份将根据一般授权配发及发行。\r\n\r\n　　公司自配售事项收取的所得款项总额及所得款项净额估计分别为约3.509亿港元及约3.451亿港元。公司拟将配售事项所得款项净额应用于以下用途：约40%将用于为在中国进行IMM2510及IMM27M的单一疗法及联合疗法的研发提供资金以治疗实体瘤；约20%将用于为IMM01(替达派西普)的研发提供资金；约10%将用于为IMM0306的研发提供资金；及约30%将用于补充公司营运资金，并作一般企业用途。\r\n\r\n　　\r\n\r\n　　【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱：news_center@staff.hexun.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}